TRAVERE THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
TRAVERE THERAPEUTICS, INC. (TVTX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$34.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$34.80M.
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$37.10M.
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $2.73M.
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $25.71M.
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$25.55M.
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$321.55M.
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$111.40M.
- TRAVERE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$278.48M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.80M 10-Q · filed 2026-08-04 | -$71.90M 10-Q · filed 2026-08-04 | -$69.17M derived: sum of 3 quarters · filed 2026-08-04 | -$43.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$37.10M 10-Q · filed 2026-05-04 | -$34.37M derived: sum of 2 quarters · filed 2026-05-04 | -$8.67M derived: sum of 3 quarters · filed 2026-05-04 | -$21.42M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $28.43M derived: sum of 2 quarters · filed 2026-02-19 | $15.68M derived: sum of 3 quarters · filed 2026-08-04 | -$25.55M 10-K · filed 2026-02-19 |
| 2025-09-30 | $25.71M 10-Q · filed 2025-10-30 | $12.95M derived: sum of 2 quarters · filed 2026-08-04 | -$28.27M 10-Q · filed 2025-10-30 | -$88.54M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$12.76M 10-Q · filed 2026-08-04 | -$53.98M 10-Q · filed 2026-08-04 | -$114.25M derived: sum of 3 quarters · filed 2026-08-04 | -$169.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$41.23M 10-Q · filed 2026-05-04 | -$101.49M derived: sum of 2 quarters · filed 2026-05-04 | -$156.30M derived: sum of 3 quarters · filed 2026-05-04 | -$226.71M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$60.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$115.08M derived: sum of 2 quarters · filed 2026-02-19 | -$185.48M derived: sum of 3 quarters · filed 2026-02-19 | -$321.55M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$54.81M 10-Q · filed 2025-10-30 | -$125.22M derived: sum of 2 quarters · filed 2025-10-30 | -$261.28M 10-Q · filed 2025-10-30 | -$351.45M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$70.41M 10-Q · filed 2025-08-06 | -$206.47M 10-Q · filed 2025-08-06 | -$296.64M derived: sum of 3 quarters · filed 2026-02-19 | -$145.91M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$136.06M 10-Q · filed 2025-05-01 | -$226.23M derived: sum of 2 quarters · filed 2026-02-19 | -$75.50M derived: sum of 3 quarters · filed 2026-02-19 | -$161.13M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$90.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $60.56M derived: sum of 2 quarters · filed 2026-02-19 | -$25.07M derived: sum of 3 quarters · filed 2026-02-19 | -$111.40M 10-K · filed 2026-02-19 |
| 2023-09-30 | $150.74M 10-Q · filed 2024-10-31 | $65.11M derived: sum of 2 quarters · filed 2024-10-31 | -$21.23M 10-Q · filed 2024-10-31 | -$87.05M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | -$85.63M 10-Q · filed 2024-08-01 | -$171.96M 10-Q · filed 2024-08-01 | -$237.78M derived: sum of 3 quarters · filed 2025-02-21 | -$307.44M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | -$86.33M 10-Q · filed 2024-05-06 | -$152.15M derived: sum of 2 quarters · filed 2025-02-21 | -$221.81M derived: sum of 3 quarters · filed 2025-02-21 | -$288.84M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | -$65.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$135.48M derived: sum of 2 quarters · filed 2025-02-21 | -$202.51M derived: sum of 3 quarters · filed 2025-02-21 | -$278.48M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$69.66M 10-Q · filed 2023-11-07 | -$136.69M derived: sum of 2 quarters · filed 2023-11-07 | -$212.66M 10-Q · filed 2023-11-07 | -$264.23M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$67.03M 10-Q · filed 2023-08-03 | -$143.00M 10-Q · filed 2023-08-03 | -$194.58M derived: sum of 3 quarters · filed 2024-02-20 | -$230.22M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$75.97M 10-Q · filed 2023-05-04 | -$127.54M derived: sum of 2 quarters · filed 2024-02-20 | -$163.18M derived: sum of 3 quarters · filed 2024-02-20 | -$202.19M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$51.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$87.21M derived: sum of 2 quarters · filed 2024-02-20 | -$126.22M derived: sum of 3 quarters · filed 2024-02-20 | -$180.09M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$35.64M 10-Q · filed 2022-10-27 | -$74.65M derived: sum of 2 quarters · filed 2022-10-27 | -$128.52M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | -$39.01M 10-Q · filed 2022-08-04 | -$92.88M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$53.87M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$169.43M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | -$146.43M 10-K · filed 2022-02-24 | |||
| 2015-06-30 | $14.13M 10-Q · filed 2015-08-10 | |||
| 2014-09-30 | -$19.56M 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | -$63.93M 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |